Strategies to achieve low-density lipoprotein cholesterol targets in high-risk patients

Area of Science:

• Cardiology
• Pharmacology
• Clinical Lipidology

Background:

• Patients at very-high cardiovascular risk often require intensive lipid-lowering therapy.
• Achieving target low-density lipoprotein cholesterol (LDL-C) levels is crucial for preventing cardiovascular events.
• Atorvastatin 80 mg may be insufficient for some patients to reach their LDL-C goals.

Purpose of the Study:

• To evaluate alternative strategies for patients with very-high cardiovascular risk who do not achieve LDL-C targets on atorvastatin 80 mg.
• To compare the safety, efficacy, and cost-effectiveness of different treatment intensification options.

Main Methods:

• Review of existing treatment options for refractory hyperlipidemia in high-risk patients.
• Comparative analysis of switching to rosuvastatin 40 mg, adding ezetimibe, or adding a PCSK9 inhibitor.
• Consideration of safety profiles, LDL-C reduction potential, cardiovascular event impact, and economic factors.

Main Results:

• Switching to rosuvastatin 40 mg is identified as a potentially attractive strategy.
• This strategy is considered based on its balance of safety, LDL-C lowering capacity, and cost.
• Limited data currently exists, necessitating further investigation.

Conclusions:

• For very-high risk patients on atorvastatin 80 mg who haven't met LDL-C targets, switching to rosuvastatin 40 mg emerges as a favorable option.
• This approach warrants further investigation due to its potential benefits.
• More studies are required to definitively confirm the impact of this strategy on LDL-C levels.